HPV-TIL infusion sees positive results in cervical cancer patients
LOS ANGELES—Data from a metastatic cervical cancer study of Lion Biotechnologies Inc.’s human papillomavirus tumor-infiltrating lymphocytes (HPV-TIL) was published recently in the Journal of Clinical Oncology. The study, conducted by the National Cancer Institute (NCI), examined whether a single infusion of HPV-TIL could induce regression in advanced HPV-positive cancers. Nine metastatic cervical cancer patients were enrolled and treated in the study, and of those, three patients experienced objective tumor responses, two of whom saw complete, ongoing remissions of 22 and 15 months, respectively, while the third saw a partial response of three months. Dr. Elma Hawkins, Lion Biotechnologies’ president and CEO, noted that “We recently amended our CRADA with the NCI to include technologies based on the HPV-TIL research. With these technologies, we look forward to expanding our clinical programs and developing new treatment options for patients with cervical cancer and other solid tumors.